Abbott and Tandem Diabetes Care have announced the wireless integration of Abbott’s FreeStyle Libre 2 Plus continuous glucose monitor with the Tandem t:slim X2 insulin pump in the US.

This announcement provides an additional treatment option for patients with diabetes requiring insulin therapy with a new, closed-loop system that can both lead to greater control over blood glucose levels and prevent complications arising from high or low blood glucose levels.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Ensuring proper management of blood glucose levels is a vital component of diabetes care, especially in those requiring insulin therapy.

High blood glucose levels, or hyperglycemia, can cause severe complications such as ketoacidosis and kidney problems while low blood glucose levels, or hypoglycemia, can lead to loss of consciousness or comas.

Insulin pumps as a standalone treatment already can lead to better glucose control through more exact measurements and easy-to-administer insulin, and the use of continuous glucose monitors such as the FreeStyle Libre 2 Plus promise to further enhance patients’ ability to control their blood glucose levels through 24/7 monitoring and early warnings of high or low blood glucose levels.

Both interventions hope to reduce diabetic complications.

The diabetes market in the US is expected to grow at a compound annual growth rate (CAGR) of 5.35% between 2021 and 2025, increasing to approximately $11.6bn by 2025, as predicted by GlobalData forecasts.

Growth in the diabetes market is precipitated by new diagnoses and technologies developed by companies such as Abbott and Tandem Diabetes Care.

According to the GlobalData Marketed Products Database, Abbott and Tandem Diabetes Care have a combined 45 devices currently on the diabetes market, of which 22 are continuous glucose monitors or insulin pumps.

Both companies have a long history of providing treatment options to diabetic patients.

The use of insulin pumps and continuous glucose monitors together provides a closed-loop solution for insulin therapy that promises to significantly improve blood glucose control in patients.

Ensuring compatibility between the various insulin pumps and continuous glucose monitors will provide additional options for diabetic patients to better manage their blood glucose levels, and ensure they remain healthy and avoid complications resulting from poor glucose control.